SCHEMBL6288765

SCHEMBL6288765

CN1C(=O)C(Cc2ccc(F)cc2)C(=O)c2oc(C(=O)NCc3ccccc3)cc21

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 3/20 0.47
ALDH1A1 P00352 3/20 0.47
LMNA P02545 2/20 0.47
KDM4E B2RXH2 2/20 0.47
DRD2 P14416 1/20 0.42
SMN1; SMN2 Q16637 5/20 0.41
CNR2 P34972 1/20 0.41
POLB P06746 1/20 0.41
KMT2A Q03164 3/20 0.41
CYP1A2 P05177 1/20 0.41
CYP2C19 P33261 1/20 0.41
MEN1 O00255 2/20 0.41
GAA P10253 1/20 0.41
TSHR P16473 1/20 0.41
MAPT P10636 2/20 0.40
TP53 P04637 2/20 0.40
CACNA1G O43497 1/20 0.40
MAPK1 P28482 1/20 0.40
RAB9A P51151 1/20 0.40
HSD17B10 Q99714 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6292804 0.80 MAPT (0.46) ALDH1A1LMNAKDM4EDRD2SMN1; SMN2
SCHEMBL6289367 0.77 CES2 (0.38) HPGDALDH1A1LMNAKDM4EKMT2A
SCHEMBL6289363 0.76 KDM4E (0.43) HPGDALDH1A1LMNAKDM4EDRD2
SCHEMBL6665657 0.74 ALDH1A1 (0.60) HPGDALDH1A1LMNAKDM4EDRD2
SCHEMBL6684556 0.74 DRD2 (0.49) ALDH1A1LMNADRD2POLBKMT2A
SCHEMBL6666902 0.72 TP53 (0.47) ALDH1A1LMNADRD2POLBKMT2A
SCHEMBL6685126 0.72 THRB (0.48) ALDH1A1DRD2POLBMAPTTP53
SCHEMBL6681355 0.70 HTR7 (0.49) ALDH1A1LMNADRD2SMN1; SMN2POLB
SCHEMBL6477867 0.70 ALDH1A1 (0.41) HPGDALDH1A1LMNAKDM4ESMN1; SMN2
SCHEMBL6678354 0.70 DRD2 (0.54) ALDH1A1LMNADRD2POLBKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6949651-B2 Fused bicyclic metalloproteinase inhibitors WARNER-LAMBERT COMPANY (US) 2005-09-27 US disclosed
US-20040034054-A1 Fused bicyclic metalloproteinase inhibitors LINCOLN FOODSERVICE PRODUCTS INC. 2004-02-19 US disclosed
WO-2004014375-A2 FUSED BICYCLIC METALLOPROTEINASE INHIBITORS WARNER-LAMBERT COMPANY LLC (US) 2004-02-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040034054-A1 Fused bicyclic metalloproteinase inhibitors MMP9, MMP1, MMP2 HPGD 500/4885ALDH1A1 337/4885LMNA 1817/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.